^
Association details:
| Biomarker: | BCR-ABL1 fusion |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | Nailike (olverembatinib) (Bcr-abl tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy and Safety of Olverembatinib-Based Therapies in Patients with Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia
Published date:
11/02/2023
Excerpt:
Olverembatinib-based regimen, 33 (100%) patients experienced remission (CR/CRi/ Morphologic leukemia-free state), and 22 (66.67%) achieved the negative minimal residual disease (MRD) of BCR-ABL1/ ABL….Olverembatinib-based therapies are generally well tolerated and efficacious for patients with Ph/BCR-ABL1-positive acute lymphoblastic leukemia.
DOI:
https://doi.org/10.1182/blood-2023-184565
Source:
Title:
The Efficacy and Safety of the Third Generation TKI Olverembatinib in Adult Ph+ Acute Lymphoblastic Leukemia with Relapsed Disease or Persistent MRD Bridging to Allo-HSCT: A Case Series from a Single Center
Published date:
11/02/2023
Excerpt:
This work suggests that Olverembatinib showed a profound response rate and was well tolerated in MRD clearance prior to allo-HSCT in Ph+ALL with disease recurrence and persistently MRD positive.
DOI:
https://doi.org/10.1182/blood-2023-184400
Source:
Title:
Olverembatinib (HQP1351) Combined with Chemotherapy Is an Effective and Safe Treatment in Patients with Philadelphia Chromosome-Positive (Ph +) Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CML-LBP) That Failed TKI-Based Regimens
Published date:
11/02/2023
Excerpt:
The 15 R/R patients (11, Ph + ALL; 4, CML-BP) received olverembatinib 30 or 40 mg on alternate days combined with VP (vindesine 4 mg once per week for 4 weeks and prednisone 1 mg/kg for 3 weeks and tapered at the fourth). A total of 13 (86%) patients achieved CR after 4-week induction therapy....Olverembatinib-based chemotherapy is effective and safe in patients with R/R and molecular resistant Ph + ALL or CML-LBP.
DOI:
https://doi.org/10.1182/blood-2023-185471
Source:
Title:
4538 Olverembatinib(HQP1351)-Based Therapy in Adults with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Advanced Chronic Myeloid Leukemia: Results of the Real-Life Study
Published date:
11/02/2023
Excerpt:
Of 56 evaluable patients, 48 (85.7%) patients reached CR/CRi….Olverembatinib-based therapy showed strong efficacy and tolerable toxicity in advanced Ph+ leukemia.
Source:
Title:
FRONTLINE COMBINATION OF OLVEREMBATINIB AND PDT-ALL-2016 PEDIATRIC INSPIRED PROTOCOL IN PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
Published date:
05/11/2023
Excerpt:
All 13 patients with a median follow-upof 8.967 months (range 6.422~11.511) enrolled achieved CR for an overall response rate of 100%...The results of olverembatinib combined with PDT-ALL-2016 pediatric-inspired protocol continue to demonstrate excellent outcome results and acceptable safety data, indicating that this strategy maybe another standard of care approach in frontline Ph-positive ALL...
Secondary therapy:
Chemotherapy
Source:
Title:
Olverembatinib (HQP1351) Enhances Antitumor Effects of Chemotherapy in Philadelphia Chromosome-Positive (Ph⁺) Acute Lymphoblastic Leukemia (ALL)
Published date:
11/02/2023
Excerpt:
Cell-based antiproliferation studies showed synergistic activity of olverembatinib in combination with vincristine or doxorubicin in Ph⁺ ALL SUP-B15 cells compared with single agents after 72 hours of treatment…. The combination significantly increased cell apoptosis compared with single agents ( p < 0.0001)....
DOI:
https://doi.org/10.1182/blood-2023-189315
